Kornimate/medical-research-clean huggingface dataset:
using santyl or bacitracin on second degree burns

Conditions: Burn, Partial Thickness

Summary: subjects who have minor, second degree burns may be enrolled in this study. subjects will receive either santyl ointment or bacitracin ointment to apply to the burn until it heals. bandages will be used to keep the burn covered while it heals. second degree burns generally leave a scar. once the burn heals, lotion and an appropriate bandage will be used to try to minimize the appearance of a scar. the study hypothesis is that burns treated with santyl will have a better scar appearance than burns treated with bacitracin. subjects enrolled in this study will make once a week visits to the university of kansas medical center outpatient burn clinic until the burn heals. the burn will be assessed for healing at these visits. once healed, visits to the clinic will be every 1-3 months for up to 1 year. at these visits, the appearance of the scar will be evaluated


Eligibility criteria:
inclusion criteria: * provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the investigator, sub-investigator or other designated study staff member has explained the study procedures, risks, and contact information. for subjects not able to provide informed consent (e.g., minors), a parent or legally authorized representative must provide consent. assent must be provided as required by the irb. * age 2 - 75 yrs, either sex, any race. * have one or more acute burns which: * • are thermal, chemical or electrical in etiology * • in aggregate cover \<10% tbsa * • are each equal to or less than 72 hrs old * • are each no more than deep partial thickness (2nd degree) * • are not visibly infected * able to take in oral fluids. * able to comply with the requirement for daily dressing changes, or have a caretaker who is able to comply. * willing to make all required study visits. exclusion criteria: * contraindications or hypersensitivity to the use of the test article or their components (e.g., known hypersensitivity to bacitracin). * embedded foreign bodies in the burn wound which cannot be immediately removed. * the burned tissue includes or is within 1 cm of the eye or genitalia. * severe perioral burns. * airway involvement or aspiration of hot liquids. * suspicion of physical abuse. * burn wound requires a skin graft. * outpatient management of the burn wound is not appropriate. * participation in another investigational clinical study within thirty (30) days of the screening visit. * current or recent (\< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease or evidence of other diseases based upon a review of medical history that, in the opinion of the investigator, would preclude safe subject participation in the study. * the medical monitor and / or investigator may declare any subject ineligible for a valid medical reason.

Keywords: burn partial thickness burn second degree burn minor burn scar santyl bacitracin outpatient burn center scar appearance kansas city university of kansas medical center kumc
study of 'vascular competence' profile and endothelial activation in the hemolytic uremic syndrome in children and adults

Conditions: Hemolytic Uremic Syndrome

Summary: the hemolytic uremic syndrome (hus) is a rare thrombotic microangiopathy (tma), affecting both children and adults. hus is characterized by the abnormal occurrence of diffuse thrombosis in the microcirculation resulting in the occurrence of ischemic events affecting especially the kidneys and is associated with hemolytic anemia. one of the major problems encountered in the management of hus is the absence of reliable marker of treatment response or relapse; conventional hematological markers being too insensitive to judge therapeutic efficacy or identify early relapse. data from the literature suggest that the endothelial cell is a major target of this syndrome. our hypothesis is that an initial micro-endothelial activation plays a critical role in the initiation and / or relapse of the disease.the main objective of this study is to define a "vascular competence" profile in a population of patients with typical or atypical hus; both in the acute phase and in remission of the disease.

the hemolytic uremic syndrome (hus) is a rare thrombotic microangiopathy (tma), affecting both children and adults. hus is characterized by the abnormal occurrence of diffuse thrombosis in the microcirculation resulting in the occurrence of ischemic events affecting especially the kidneys and is associated with hemolytic anemia.its prognosis is severe, with a mortality of 1% in children, 10% in adults and the occurrence of renal failure in 50% of cases.in its typical form, hus occurs in the aftermath of a diarrheic intestinal infection by bacteria which produce a shiga toxin. in its unusual shape, which affects both children and adults, there are genetic abnormalities alternate way of regulating complement proteins explaining frequent relapses.one of the major problems encountered in the management of hus is the absence of reliable marker of treatment response or relapse; conventional hematological markers being too insensitive to judge therapeutic efficacy or identify early relapse. data from the literature suggest that the endothelial cell is a major target of this syndrome. our hypothesis is that an initial micro-endothelial activation plays a critical role in the initiation and / or relapse of the disease through the sudden release of high molecular weight ultralarge von willebrand factor (ul-vwhf) and procoagulant endothelial microparticles.the main objective of this study is to define a "vascular competence" profile in a population of patients with typical or atypical hus; both in the acute phase and in remission of the disease.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of typical or atypical hus in acute phase exclusion criteria: * patient with positive serological screening test for infection with the hiv. * patients with a history of cancer. * patients who have undergone organ transplantation or bone marrow. * patient with a vivid picture of autoimmune thrombotic thrombocytopenic purpura
experiences with automated surgical drainage in cardiac surgery

Conditions: Hemorrhage

Summary: the purpose of this study is to evaluate the thoraguard surgical drainage system in a real-world clinical environment. it is believed that this system will offer functional and clinical benefits over the current standard of care system for the removal of surgical fluids following cardiac surgery. observations, experiences, and outcomes in a single hospital setting will be collected for the thoraguard surgical drainage system.

the thoraguard system is intended for use for drainage of blood, fluids, and gases following cardiac and thoracic surgery. the system consists of an electronic control module, drainage kit (fluid collection canister and drainage line), and chest tube kit with novel chest tube. the system continuously monitors chest tube and drainage line patency, automatically clears the chest tube and drainage line from build-up, and provides digital readings of fluid output trends. additionally, the system has patient safety alarms to notify clinical staff of an unexpected event associated with post-operative drainage. these functions offer significant improvements over current standard of care. reliable post-operative drainage, reduced workload, and decreased variability in chest tube maintenance procedures have the potential to increase patient safety, reduce complications, and improve patient experience.

Eligibility criteria:
inclusion criteria: * adult (age ≥ 18) * patient undergoing non-emergent cardiac surgery * anticipated requirement for mediastinal chest tube drainage exclusion criteria: * emergency surgery * re-do surgery * prior cardiac surgery * congenital cardiac disease or deformation * transplant surgery * ventricular assist device surgery * suspected pulmonary air leak * atrial fibrillation * in the opinion of the investigator the patient is unsuitable for the study for any other legitimate reason including incarceration, pre-existing medical or psychiatric condition, or interfering medications * known previous or concurrent enrollment in a clinical trial that, in the opinion of the investigator, might interfere with the objectives of this clinical trial * pregnancy
exploratory study for dry mouth in patients with sjögren's syndrome

Conditions: Xerostomia; Sjogren's Syndrome

Summary: the purpose of this study is to exploratively investigate the clinical efficacy of rebamipide on dry mouth in patients with sjögren's syndrome in comparison with placebo.


Eligibility criteria:
inclusion criteria: 1. patients with sjögren's syndrome (revised japanese criteria for sjögren's syndrome (1999): 1998 research report on immunological intractable diseases specified by the japanese ministry of health and welfare) 2. patients aged 20 years or older at time of consent 3. patients with dry mouth 4. patients with decreased salivation exclusion criteria: 1. patients who have developed dry mouth clearly due to a cause other than sjögren's syndrome 2. patients in whom saxon test cannot be performed (artificial tooth, tooth implant, etc.) 3. patients who have received rebamipide within 3 months prior to obtaining informed consent 4. patients who are pregnant, possibly pregnant, or lactating 5. patients with a history of hypersensitivity to rebamipide 6. patients who have received any other investigational drug within 3 months prior to obtaining informed consent 7. patients who are otherwise judged inappropriate for inclusion in the study by the investigator or subinvestigator
a predictive score system for aki following pediatric cardiac surgery

Conditions: Congenital Heart Disease; Surgery--Complications; Acute Kidney Injury

Summary: acute kidney injury (aki) has been recognized as a typical post- operative complication among the children undergoing surgical repair of a congenital cardiac defect. it is associated with increased morbidity and mortality in the intensive care unit and a higher utilization of hospital resources. however, how to precisely identify those who have greater hazard to encounter postoperative aki seems ambiguous.

the development of aki is common following cardiac surgery whether in adult or pediatric population. not only severe aki like dialysis support, but also mild kidney injury has profound influence on increased subsequent morbidities and mortality. pediatric patients who undergo cardiac procedures are characterized by lower weight, younger age, complicated cardiac anomaly and poor resistance to surgical insults. thus, in comparison with adults, their aki risk is relatively higher. at present there has been no specific intervention regarding aki prevention and therapy. establishing a risk score based on patient characteristics and surgical information to effectively predict postoperative aki risk is therefore imperative. it can serve as a decision-making tool to facilitate patient management with regard to kidney prognosis. this program is aimed at developing and internally validating a aki risk score post cardiac surgery in a chinese pediatric population.

Eligibility criteria:
inclusion criteria: 1. \< 18 years old 2. pediatric patients undergoing cardiac surgery in fuwai hospital exclusion criteria: 1. supported by dialysis for renal failure prior to cardiac procedure 2. previously received a renal transplant 3. lack of preoperative or postoperative serum creatinine measurements 4. guardians' refusal on informed consent sign

Keywords: pediatric cardiac surgery acute kidney injury prediction
assessment of the impact of covid-19 pandemic on residents training and mental health in poland

Conditions: SARS-CoV-2

Summary: the aim of study is to investigate the impact of sars-cov-2 on ophthalmology training programs among residents. to the best of our knowledge this study is the first of its kind in poland. the impact of covid-19 on ophthalmology training programs is largely unknown as there are only few studies assessing the above issue from the resident's point of view.

the novel coronavirus sars-cov-2, responsible for coronavirus disease 2019 (covid-19), was first identified at the end of the year 2019 in wuhan (china). a rapid spread of the disease resulted in global threat to public health. on 11 march 2020 the world health organization (who) announced the state of pandemic. in poland, the first confirmed case of covid-19 was reported on 4 march 2020 and subsequent growing number of patients has placed tremendous strain on healthcare system. the crisis situation prompted immediate action to divert healthcare resources for the treatment of patients with covid-19 and to limit the spread of the infection. in accordance with the decision of the minister of health of march 13th, 2020, more than twenty hospitals were established to admit only the sars-cov-2 affected patients. moreover, all hospitals were recommended to limit their planned activity and to perform only urgent and emergency services. the investigators hypothesize that those changes in healthcare system and restrictions established in public area during pandemic caused significant difficulties in residency training considering clinical and surgical practice as well as didactic activities. in spite of gradual reopening the routine services over the last few months, social distancing rules are still in force. accordingly, different methods of virtual teaching were introduced including, inter alia, organisation of courses, lectures and conferences in form of on-line meetings. the aim of current study is to investigate the impact of sars-cov-2 on ophthalmology training programs among residents. to the best of our knowledge this study is the first of its kind in poland. the impact of covid-19 on ophthalmology training programs is largely unknown as there are only few studies assessing the above issue from the resident's point of view. the investigators believe that this investigations will address this gap in the literature and could be used to initiate the new solutions in order to maintain successful residency training during pandemic. opinions regarding the efficiency of e-learning methods and on-line meetings may be crucial to innovate the conventional teaching way permanently in the future.

Eligibility criteria:
inclusion criteria: * male and female in the age of 25-35 during residence training exclusion criteria: * lack of consent for participating in survey

Keywords: residents training
effects of crocuvis+® on computer vision syndrome, sleep and mood disorders

Conditions: Computer Vision Syndrome; Sleep Disorder; Mood Disorders

Summary: previous research has shown the efficacy of crocuvis+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. the main objective of this study is to evaluate the efficacy of crocuvis® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.


Eligibility criteria:
inclusion criteria: * cvs-q© score ≥6. * age between 18 and 40 years (both inclusive). * exposure to digital devices 4 hours a day, at least five days a week or more and maintain the same level of exposure throughout the study period. exclusion criteria: * monocular corrected distance visual acuity \>0.0 logmar. * ocular pathology under treatment at the time of the study. * previous ocular surgery that could affect the tear film or the ocular surface. * ocular surface disease index (osdi) questionnaire score ≥13. * previous diagnosis or history of dry eye syndrome and/or blepharitis. * regular (daily) use of rigid or soft contact lenses ≥3 days a week. * regular use of any ocular lubricant. * history of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment. * systemic disease: 1. uncontrolled hypertension (systolic/diastolic blood pressure \>140/90 mmhg). 2. uncontrolled diabetes mellitus (fasting blood glucose level \>180 mg/dl). 3. rheumatoid arthritis. 4. tumor disease. 5. active hepatitis (type b and c). 6. active infectious disease. 7. kidney disease that compromises diuresis. * current systemic treatment or in the last 3 months with drugs that may interfere with the results, for example: 1. opioids. 2. antipsychotics. 3. antibiotics (tetracyclines, sulfonamides) 4. antiarthritic drugs (hydroxychloroquine) 5. hypotensive drugs (beta-blockers) 6. anticoagulants (heparin, warfarin, or clopidogrel) 7. antidepressants (such as fluoxetine, among others) 8. hypnotics (eg, benzodiazepines) * habitual smoker and/or alcohol drinker. more than 3 cigarettes per day and/or more than 3 standard drink units (sdu) per week, including weekends. sdu is defined as the consumption of 10 ml of alcohol. * regular job with rotating shifts including night shift in the last month (including weekends). * pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant. * participation in another clinical trial in the last 3 months. * take any type of dietary supplements with botanical components in the last month.
clinical outcomes in patients referred to pulmonary rehabilitation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lung, characterized by chronic cough, dyspnea, and sputum production, which often misunderstood as aging or catching a cold. these symptoms may be progressive over time. to provide better disease management and early detecting, pulmonary rehabilitation is now considered a fundamental component of the integrated disease management of this population. however, few studies have evaluated the beneficial outcomes in patients referred to pulmonary rehabilitation. therefore, the purpose of this study is to investigate the clinical outcomes in patients referred to pulmonary rehabilitation in national taiwan university hospital.


Eligibility criteria:
inclusion criteria: 1. age \> 20 years old 2. patients with chronic respiratory disease diagnosed by physician that referred to pulmonary rehabilitation in national taiwan university hospital including, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, bronchiectasis 3. can cooperate with pulmonary rehabilitation clinic exclusion criteria: 1. angina, acute myocardial infarction in the previous one month 2. pregnancy
safety, tolerability, and pharmacokinetic study of evp-6124 in patients with alzheimer's disease

Conditions: Alzheimer's Disease; Central Nervous System Diseases

Summary: this study is being conducted to determine the safety, tolerability, and pharmacokinetics (pk) of three different doses of an investigational medication, evp-6124, in individuals with mild to moderate alzheimer's disease who are also taking an alzheimer's medication (achei \[acetylcholinesterase inhibitor\]: either donepezil or rivastigmine). in addition, pk of achei medications will be assessed. cognitive function will be evaluated on an exploratory basis.

this is a randomized, double-blind, placebo-controlled, phase 1b safety study of three dose levels of evp-6124 in subjects with mild or moderate alzheimer's disease and who are taking an achei medication (donepezil or rivastigmine). study drug will be supplied as capsules and will be orally administered once daily for a total of 28 days. eligible subjects will be admitted to an inpatient study unit on day -2 (two days before the first dose of study drug is administered) and will remain confined to the inpatient study unit for a total of five days. starting on day 4, subjects will continue the study in the outpatient setting, with study visits on days 7, 14, 21, and 28. safety assessments, pk sampling, and cognitive testing will be performed inpatient and at each study visit.

Eligibility criteria:
inclusion criteria: * male and post-menopausal or surgically sterile female pts * 50-90 yrs old, who meet clinical criteria for probable alzheimer's disease (mini-mental state examination of 18-26; hachinski ischemic score ≤4) * must be taking donepezil or rivastigmine for at least 3 mos. exclusion criteria: * unstable medical condition that is clinically significant in the judgment of the investigator; major organ system dysfunction * untreated hypothyroidism * insufficiently controlled diabetes mellitus * diagnosis of major depression requiring antidepressant medications within the last 5 years * stroke within 6 months before screening, or concomitant with onset of dementia * certain concomitant medications

Keywords: alzheimer's disease central nervous system diseases pharmacokinetics cognition
clinical outcomes and global epidemiology -data coordinating center

Conditions: Acinetobacter Infections

Summary: the primary objective is to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with acinetobacter bloodstream infection. secondary objectives include the following: to determine the impact of inactive empiric antimicrobial therapy, defined as receipt of empiric antimicrobial therapy with no in vitro activity against the offending isolate for at least 24hrs, on the outcome (end points defined below) of patients with acinetobacter bloodstream infection. to determine the impact of carbapenem resistance and pan-drug resistance (defined as resistance to all antimicrobials except colistin and/or tigecycline if these agents were tested) on the outcome of patients with acinetobacter bloodstream infection. to assess the efficacy of varying definitive therapies on the outcome of patients with acinetobacter bloodstream infection. to characterize the molecular epidemiology of acinetobacter on a global level, as determined by pulsed-field gel electrophoresis (pfge) and other techniques, and to assess whether patient outcomes are clonally related and to characterize the mechanisms of resistance in acinetobacter on a global scale.

medical records will be reviewed and information collected from charts to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with acinetobacter bloodstream infection. 24 sites will participate and all information will be loaded into a password protected database.

Eligibility criteria:
inclusion criteria: * acinetobacter bloodstream infection exclusion criteria: * does not meet entry criteria

Keywords: acinetobacter bloodstream infection isolate